Overview

Fresolimumab In Systemic Sclerosis

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.

Phase:

Phase 1

Details

Lead Sponsor:

Boston University

Treatments:

Antibodies, Monoclonal